Lymphedema pp 465-469 | Cite as


  • LeAnne M. Fox


Lymphatic filariasis is caused by infection with three species of parasite: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Currently, there are an estimated 1.3 billion people living in endemic areas in 81 countries and 120 million people are infected. More than 90% of these infections are caused by W. bancrofti for which humans are the only natural host.


Endemic Area Lymphatic Vessel Adult Worm Lymphatic Filariasis Mass Drug Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Michael E, Bundy DAP, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996;112:409-428.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. Global Programme to Eliminate Lymphatic Filariasis (GPELF) Progress Report 2000–2009 and Strategic Plan 2010–2020. 2010; 6–8.Google Scholar
  3. 3.
    Merelo-Lobo AR, McCall PJ, Perez MA, et al. Identification of the vectors of lymphatic filariasis in the Lower Shire Valley, southern Malawi. Trans R Soc Trop Med Hyg. 2003;97(3):299-301.PubMedCrossRefGoogle Scholar
  4. 4.
    Ramaiah KD, Das PK. Seasonality of adult Culex quinquefasciatus and transmission of bancroftian filariasis in Pondicherry, south India. Acta Trop. 1992;50(4):275-283.PubMedCrossRefGoogle Scholar
  5. 5.
    Chang MS. Operational issues in the control of the vectors of Brugia. Ann Trop Med Parasitol. 2002;96(2):S71-S76.PubMedCrossRefGoogle Scholar
  6. 6.
    Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PloS Negl Trop Dis. 2007;1(3):e88.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Conner FW. Filarial periodicity with observations and on the mechanisms of migration of the microfilariae and from parent worm to the blood stream. PR Public Health Trop Med. 1931;6:263.Google Scholar
  8. 8.
    Shenoy RK, Suma TK, Kumaraswami V, et al. Lymphoscintigraphic evidence of lymph vessel dilation in the limbs of children with Brugia malayi infection. J Commun Dis. 2008;40(2):91-100.PubMedGoogle Scholar
  9. 9.
    Fox LM, Furness BW, Haser JK, et al. Ultrasonographic examination of Haitian children with lymphatic filariasis: a longitudinal assessment in the context of antifilarial drug treatment. Am J Trop Med Hyg. 2005;72:642-648.PubMedGoogle Scholar
  10. 10.
    Lammie PJ, Reiss MD, Dimock KA, et al. Longitudinal analysis of the development of filarial infection and antifilarial immunity in a cohort of Haitian children. Am J Trop Med Hyg. 1998;59:217-221.PubMedGoogle Scholar
  11. 11.
    Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Bull World Health Org. 2001;6:582-606.Google Scholar
  12. 12.
    Taylor MJ, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today. 1999;15:437-442.PubMedCrossRefGoogle Scholar
  13. 13.
    Hise AG, Gillette-Ferguson I, Pearlman E. The role of endosymbiotic Wolbachia bacteria in filarial disease. Cell Microbiol. 2004;6:97-104.PubMedCrossRefGoogle Scholar
  14. 14.
    Hoerauf A, Mand S, Fischer K, et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003;192:211-216.PubMedCrossRefGoogle Scholar
  15. 15.
    Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet. 2001;358:1873-1875.PubMedCrossRefGoogle Scholar
  16. 16.
    Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health. 2007;12(12):1433-1441.PubMedCrossRefGoogle Scholar
  17. 17.
    Dreyer G, Medeiros Z, Netto MJ, et al. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg. 1999;93:413-417.PubMedCrossRefGoogle Scholar
  18. 18.
    Olszewski WL, Jamal S, Manokaran G, et al. Bacteriologic studies of blood, tissue fluid, lymph, and lymph nodes in patients with acute dermatolymphangioadenitis (DLA) in course of ‘filarial’ lymphedema. Acta Trop. 1999;73:217-224.PubMedCrossRefGoogle Scholar
  19. 19.
    Dreyer G, Noroes J, Figueredo-Silva J, et al. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today. 2000;16:544-548.PubMedCrossRefGoogle Scholar
  20. 20.
    Kazura JW, Bockarie M, Alexander N, et al. Transmission intensity and its relationship to infection and disease due to Wuchereria bancrofti in Papua New Guinea. J Infect Dis. 1997;176:242-246.PubMedCrossRefGoogle Scholar
  21. 21.
    Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog. 2006;2(9):e92.PubMedCrossRefGoogle Scholar
  22. 22.
    Dreyer G, Addiss DG, Dreyer P, et al. Basic Lymphoedema Management: Treatment and Prevention of Problems Associated with Lymphatic Filariasis. Hollis: Hollis Publishing Co.; 2002.Google Scholar
  23. 23.
    Addiss DG, Louis-Charles J, Roberts J, et al. Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis. PloS Negl Trop Dis. 2010;4(4):e688.CrossRefGoogle Scholar
  24. 24.
    Kerketta AS, Babu BV, Rath K, et al. A randomized clinical trial to compare the efficacy of three treatment regimens along with footcare in the morbidity management of filarial lymphoedema. Trop Med Int Health. 2005;10:698-705.PubMedCrossRefGoogle Scholar
  25. 25.
    WHO. Informal consultation on preventing disability from lymphatic filariasis, WHO, Geneva, August 2006. Wkly Epidemiol Rep. 2006;81:373-383.Google Scholar
  26. 26.
    Evans DB, Gelband H, Vlassoff C. Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop. 1993;53:1-26.PubMedCrossRefGoogle Scholar
  27. 27.
    Ottesen EA. The global programme to eliminate lymphatic filariasis. Trop Med Int Health. 2000;5:591-594.PubMedCrossRefGoogle Scholar
  28. 28.
    Ottesen EA, Hooper PJ, Bradley M, et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PloS Negl Trop Dis. 2008;2(10):e317.PubMedCrossRefGoogle Scholar
  29. 29.
    Chu BK, Hooper PJ, Bradley MH, et al. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PloS Negl Trop Dis. 2010;4(6):e708.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • LeAnne M. Fox
    • 1
  1. 1.Division of Parasitic Diseases and Malaria, Center for Global HealthCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations